A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Public ClinicalTrials.gov record NCT04817007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis
Study identification
- NCT ID
- NCT04817007
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 216 participants
Conditions and interventions
Conditions
Interventions
- BMS-986158 Drug
- Fedratinib Drug
- Ruxolitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 21, 2021
- Primary completion
- Aug 30, 2028
- Completion
- Aug 30, 2028
- Last update posted
- May 7, 2026
2021 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0069 | Newport Beach | California | 92663 | — |
| Local Institution - 0090 | Lake Mary | Florida | 32746 | — |
| Local Institution - 0043 | New Orleans | Louisiana | 70112 | — |
| Local Institution - 0038 | Worcester | Massachusetts | 01655 | — |
| Local Institution - 0033 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0045 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0076 | Chapel Hill | North Carolina | 27514 | — |
| Local Institution - 0042 | Pittsburgh | Pennsylvania | 15224 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04817007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04817007 live on ClinicalTrials.gov.